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Several cutaneous inflammatory diseases and their
clinical phenotypes are recapitulated in animal mod-
els of skin disease. However, the identification of
shared pathways for disease progression is limited by
the ability to delineate the complex biochemical
processes fundamental for development of the dis-
ease. Identifying common signaling pathways that
contribute to cutaneous inflammation and immune
function will facilitate better scientific and therapeutic
strategies to span a variety of inflammatory skin
diseases. Aberrant antimicrobial peptide (AMP) ex-
pression and activity is one mechanism behind the
development and severity of several inflammatory
skin diseases and directly influences the susceptibility
of skin to microbial infections. Our studies have
recently exposed a newly identified pathway for
negative regulation of AMPs in the skin by the
cholinergic anti-inflammatory pathway via acetylcho-
line (ACh). The role of ACh in AMP regulation of
immune and permeability barrier function in kerati-
nocytes is reviewed, and the importance for a better
comprehension of cutaneous disease progression by
cholinergic signaling is discussed.
Journal of Investigative Dermatology (2012) 132, 28–42;
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INTRODUCTION AND SCOPE OF THE PROBLEM
Inflammatory skin diseases are a major cause of morbidity
and mortality for patients, where the atypical cytokine and
cellular milieu creates a reservoir for cutaneous infection and
diminished barrier function. Loss of skin permeability barrier
function leads to excessive water loss and penetration of
irritants, allergens, and microbes. Moreover, barrier function
studies demonstrate that physical cutaneous permeability
barrier (e.g., electrolyte and water movement) and the
chemical antimicrobial barrier (e.g., antimicrobial peptide
(AMP)) are codependent (Ahrens et al., 2011). Studies have
shown that a diminished permeability barrier function is
associated with reduced lipid synthesis and AMP production
(Aberg et al., 2008). Injury and infection function as a trigger
for the development of numerous skin diseases by providing a
stimulus for activation of distinct inflammatory pathways.
Infections caused by viral, bacterial, or fungal agents can not
only initiate disease directly, but also further exacerbate
inflammatory skin diseases. Although staphylococcal and
streptococcal infections often precede the development of
psoriasis, which is generally considered the most stress-
responsive skin disease compared with atopic dermatitis (AD)
and acne vulgaris (Griffiths and Richards, 2001), psoriatic
plaques are generally resistant to infection (Raychaudhuri and
Raychaudhuri, 1993). AD is also initiated and worsened by
prolonged psychological stress and injury or infection;
however, lesions from these patients tend to be more
susceptible to colonization and infection following develop-
ment of the disease (Ong et al., 2002; Nomura et al., 2003).
Thus, the inflammatory pathways activated in response to
primary injury or infection further exacerbate the barrier
defect to facilitate disease progression. The current paradigm
tends to categorize inflammatory responses as either pro- or
anti-inflammatory, but fails to recognize the unifying
concepts that initiate these injury and infection response
patterns.
Both anecdotal and clinical evidence for the role of
perceived stress in the pathophysiology of skin diseases has
existed for decades (Kimyai-Asadi and Usman, 2001; Picardi
and Abeni, 2001). This effect is 2-fold, where stress can
initiate the onset of symptoms and, at a later time, the disease
manifestations can become a major source of stress for the
patients to further exacerbate the clinical manifestations of
their disease. Although the influence of glucocorticoids (GCs)
and catecholamines on skin barrier and innate immune
function have been more thoroughly studied in the context of
skin infection and disease progression, less attention has been
given to the role of the cholinergic system on epidermal
permeability barrier and innate immune function. Our recent
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investigations into how the neuroendocrine system influences
epidermal AMP function has uncovered a newly recognized
pathway for the negative regulation of AMPs in the skin
through the activation of nicotinic acetylcholine (ACh)
receptors (nAChRs) by ACh. Here, we will review the current
mechanisms related to cholinergic signaling believed to
trigger stress-induced skin disorders by modulating keratino-
cyte innate immune and barrier function, with a focus on
AMP regulation.
THE HPA AXIS, ADRENERGIC PATHWAY, AND THE
CHOLINERGIC PATHWAY OF THE STRESS RESPONSE
Within the last few decades, a significant amount of evidence
suggests that an elaborate communication network exists
between the nervous, endocrine, and innate immune systems
to delicately balance the response to microbial invasion and/
or injury. The immediate host reaction to physical insult, such
as wounding or pathogen challenge, or to psychological
stress is the rapid activation of the evolutionarily conserved
‘‘fight or flight’’ response. This initial danger-associated
response promotes inflammation and immune cell infiltration
to combat an infectious threat or injury, which is then
followed by immunosuppression via neuroendocrine path-
ways to return to homeostasis (Tracey, 2002). Once the
stressors are eliminated, the biochemical profile of the
organism is expected to return to normal physiological
homeostasis. However, prolonged activation of neuroendo-
crine responses can directly promote systemic immunosup-
pression (reviewed in Dhabhar, 2000).
Stress leads to activation of the parasympathetic and
sympathetic nervous systems, as well as the hypothalamic–-
pituitary–adrenal axis (HPA). Activation of the parasympa-
thetic nervous system results in the release of ACh from nerve
fibers innervating the organs, resulting in activation of nAChR
and/or muscarinic ACh receptors (mAChRs). Activation of
the sympathetic nervous system results in the release of
epinephrine/norepinephrine, activating a- or b-adrenergic
receptors. Parasympathetic nervous system and sympathetic
nervous system activation mediates a variety of immuno-
logical and homeostatic functions, including changes in
cellular proliferation, differentiation, and migration (Maes-
troni, 2006; reviewed in Slominski and Wortsman, 2000).
Activation of the hypothalamic–pituitary–adrenal axis stimu-
lates the release of several neuroendocrine mediators, such as
GCs (e.g., cortisol), into the bloodstream, which function
upon specific cell populations and tissues to generate an
immunosuppressive effect and return proinflammatory
mediators to normal, baseline levels (Herman and Cullinan,
1997). However, prolonged or chronic stress tends to be
immunosuppressive, in part, by dampening cytokine produc-
tion and immune cell phagocytic capacity (Abang et al.,
2006; Ashcraft and Bonneau, 2008; Dhabhar et al., 2010).
This pathway was later coined the ‘‘cholinergic anti-
inflammatory pathway’’ after efferent activity in the vagus
nerve was found to inhibit local proinflammatory production
of cytokines by signaling through the innervated regions
of major organs involved in the response to endotoxin,
without affecting the production of anti-inflammatory
cytokines (Tajima et al., 1996; Bernik et al., 2002a; Saeed
et al., 2005; Pavlov et al., 2006). Our studies recently
revealed that cholinergic activation in non-neuronal kerati-
nocytes is a major pathway involved in the suppression of
keratinocyte antimicrobial activity, and is the focus of this
review.
LINKING STRESS RESPONSES TO EPIDERMAL INNATE
IMMUNE FUNCTION DURING INJURY OR INFECTION
Dynamic cross talk is required between the nervous,
endocrine, and immune systems to regulate inflammatory
processes across a vast array of cell types and tissues
(Elenkov et al., 2000; Tracey, 2002). Many of the neuroen-
docrine ligands and ligand receptors derived from all three
branches of the stress-response pathways participate in
cellular communication and are expressed by immune,
nerve, and epidermal cells. For example, macrophages
release tumor necrosis factor (TNF)-a during injury or
infection to amplify the inflammatory response by stimulat-
ing the release of proinflammatory mediators, including IL-1,
reactive oxygen species, nitric oxide, and eicosanoids
(Wood et al., 1992; Nickoloff and Naidu, 1994). During
the initial fight or flight response, all three pathways of the
stress response are coordinately activated to modulate
inflammation. For example, epinephrine/norepinephrine
can block macrophage activation and dampen production
of TNF-a and other proinflammatory cytokines (Chrousos,
2000; Molina, 2001; Molina et al., 2001). Alternatively,
epinephrine/norepinephrine can induce the release of the
anti-inflammatory cytokine, IL-10, from monocytes (van der
Poll et al., 1996; Woiciechowsky et al., 1998). In parallel,
ACh has the capacity to inhibit macrophage activation and
release of proinflammatory cytokines, such as TNF-a, IL-1,
and high-mobility group protein B1 (Borovikova et al.,
2000), ultimately limiting tissue damage caused by excessive
inflammation.
Psychological stress was initially found to delay wound
healing and diminish epidermal barrier homeostasis (Kiecolt-
Glaser et al., 1995; Denda et al., 1998; Marucha et al.,
1998; Garg et al., 2001; Rojas et al., 2002), mediated through
the activation of both GC and adrenergic signaling pathways
in the skin. Mice subjected to insomnia stress for 3 days
demonstrated a decrease in the protein abundance of
two major skin AMPs, cathelicidin antimicrobial peptide
(human; CAMP) and mouse beta defensin-3, compared with
unstressed mice. Moreover, these mice were more suscep-
tible to cutaneous group A Streptococcus infection, as
indicated by larger skin lesions compared with unstressed
mice. The adverse affect of stress on AMP expression and
lesion size was reversed by systemic administration of
RU-486, a GC/progesterone antagonist, suggesting that GC-
receptor-mediated activation was involved in the suppression
of AMP expression (Aberg et al., 2007). These studies were
the first to establish a direct connection between stress
and AMP expression in the context of cutaneous infection.
Earlier studies showed that catecholamines promote the
release of fully processed active AMPs from the skin
surface (Benson and Hadley, 1969; Zasloff, 1987). More
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recent observations in keratinocytes demonstrated that
b-adrenergic activation impairs cell motility and wound
closure, indicating a pathway by which stress impairs
cutaneous healing (Pullar et al., 2006; Sivamani et al.,
2009). Together, mediators of the stress response can directly
or indirectly influence several key components of epidermal
defense.
THE EVOLUTION OF THE CHOLINERGIC
‘‘INFLAMMATORY REFLEX’’
During embryonic development, the skin and nervous
system are both derived from the neuroectoderm. Conse-
quently, many key factors that influence neuronal central
nervous system activities also contribute to non-neuronal
cellular function, as most immune and epidermal cells
express several components of the cholinergic system
(reviewed in Radek, 2010). ACh can facilitate the commu-
nication between immune and epidermal cells to mount a
physiological response to injury or infection. Langerhans
cells, mast cells, neutrophils, and macrophages all express
various components required for cholinergic signaling
via ACh, including the enzymes mediating ACh synthesis
and degradation, as well as nAChR and mAChR subunits
(reviewed in Kawashima and Fujii, 2004). Previous work
has identified that the a7nAChR is the primary receptor
involved in the cholinergic anti-inflammatory pathway in
bone marrow-derived immune cells (Wang et al., 2003).
During bacterial infection or following injury, TNF-a
functions as an inflammatory input signal to the autonomic
nervous system, which reflexively responds by stimu-
lating the vagus nerve, resulting in activation of humoral
anti-inflammatory responses (Tracey, 2002). Preclinical
animal studies have shown that vagus nerve stimu-
lators designed to promote release of ACh are extremely
effective in suppressing cytokine-mediated inflammation
and damage through a7nAChRs expressed on cytokine-
producing cells (e.g., macrophages and dendritic cells).
These observations exposed a central regulatory role for
vagus nerve-mediated ACh activity in suppressing systemic
cytokine release in organs and in serum, and attenuation of
disease severity in response to a variety of inflammatory
stimuli.
Keratinocytes comprise the epidermal non-neuronal
cholinergic system, where the ‘‘non-neuronal cholinergic
system’’ refers to cholinergic signaling pertaining to or
composed of nonconducting cells of the nervous system
(e.g., cells other than neurons; Grando et al., 1993, 2007).
ACh released from keratinocytes in response to pathogen
challenge or wounding likely contributes to the regulation of
local immune responses, and potentially that of infiltrating
immune cells. Keratinocytes express different nAChR sub-
types during the course of epidermal differentiation, and
knockout animals for several nAChR subtypes display diverse
phenotypes (reviewed in Grando et al., 2006). Although the
role of cholinergic signaling in keratinocyte proliferation,
differentiation, and migration has been well described
(reviewed inGrando et al., 2006), the role in keratinocyte
innate immunity remains elusive.
Our new observations identifying cholinergic activation as
a mechanism for keratinocyte AMP regulation supports the
paradigm upon which the inflammatory reflex is based to
describe a global response involving a biochemical triad of
the nervous, immune, and cutaneous systems to orchestrate
anti-inflammatory pathways. The cholinergic pathway in
both neuronal and non-neuronal cells is likely activated by
the prolonged stress response in an attempt to restrain
excessive pathological inflammation (Tracey, 2007). Ulti-
mately, this creates a detrimental negative feedback loop in
the epidermis that results in immunosuppresion of AMP
production and activity, and likely other proinflammatory
cytokines, to diminish the capacity of the epidermis to resist
infection (Figure 1). Therefore, it is of critical importance to
identify which nAChR subtype(s) is/are primarily involved in
AMP expression. Our work in both keratinocytes and mouse
models of nAChR activation determined that the a7nAChR
subtype is a major factor involved in AMP suppression in the
epidermis (Radek et al., 2010), which parallels the work by
Kevin Tracey and colleagues (Borovikova et al., 2000; Bernik
et al., 2002a, b; Tracey, 2002, 2007). Current studies in our
laboratory are further exploring the mechanism behind
cholinergic regulation of AMPs in keratinocytes. The poten-
tial involvement of aberrant cholinergic activation in the
development of cutaneous disease in the context of AMPs
and barrier function is later discussed and is summarized in
Table 1.
Stress
Efferent
vagus nerve
stimulation
Non-
neuronal
ACh
?
ACh
nAChR AMPproduction
Lipid
synthesis
Local inflammation
and
disease progression
Cholinergic feedback loop
Neuronal
ACh
Injury,
infection
Figure 1. Elements of the systemic and local cholinergic anti-inflammatory
pathway proposed to augment cutaneous disease progression. Stress can
initiate a systemic response to activate the systemic cholinergic anti-
inflammatory pathway through an efferent relay and stimulate acetylcholine
(ACh) release from neuronal cells in the skin (e.g., nerve cells) to potentially
function on keratinocytes. The non-neuronal cholinergic system in
keratinocytes is capable of producing ACh that can be released into the
extracellular space to activate nicotinic ACh receptors (nAChRs).
Consequently, nAChR activation dampens antimicrobial peptide (AMP)
production and epidermal barrier integrity. Injury or infection during stress
can either initiate or exacerbate existing skin pathologies. Episodes of more
frequent or severe outbreaks of skin disease can signal a negative feedback
loop back to the brain to provoke a secondary stress response to further
suppress keratinocyte AMP and barrier function.
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EVIDENCE FOR A CUTANEOUS NON-NEURONAL
CHOLINERGIC SYSTEM
The non-neuronal cholinergic system in keratinocytes is
primarily regulated through the binding of the neurotrans-
mitter, ACh, to nAChRs and mAChRs, classified on the basis
of their respective agonists, nicotine and muscarine (Grando
et al., 2006). ACh is synthesized from coenzyme A and
choline by choline acetyltransferase and is degraded by
acetylcholinesterase. Keratinocytes have the capacity to
synthesize, process, store, and release ACh that can bind
to nAChRs or mAChRs expressed on their cell surface to
regulate an array of cellular processes, including migration,
differentiation, proliferation, and apoptosis (Grando, 1993;
Denda et al., 2000) Keratinocyte cells can synthesize an
average of 21017 mol and secrete 71019 mol of ACh
per minute (Grando et al., 1993). However, a gradient of ACh
expression throughout the epidermis is observed, with highest
ACh levels present in the uppermost epidermal compartment
(Nguyen et al., 2001), likely because the highest amounts of
choline acetyltransferase, the ACh-degrading enzyme, is
located predominantly in the basal layer (Johansson and
Wang, 1993, 2006; Klapproth et al., 1997). This intricate
ACh-dependent network is referred to as the non-neuronal
cholinergic system (Klapproth et al., 1997; Wessler et al.,
1998, 1999).
The nAChR superfamily of ligand-gated ionotropic recep-
tors comprise homo- or heterotypic combinations of nine a
subunits (a2–a10) and three b subunits (b2–b4; Steinbach,
1990). During the course of keratinocyte differentiation, the
expression of nAChR subunits and ACh regulatory enzymes is
modified accordingly to support essential functions required
for the specific microenvironment of each stratified layer of
Table 1. A select list of cutaneous diseases involving aberrant cholinergic signaling
Skin disease
Factors contributing to disease pathology and
complementary evidence to indicate involvement of
cholinergic signaling References
Atopic dermatitis kExpression of AMPs, including hbD2, hbD3, and
cathelicidin, compared with psoriatic skin
kExpression of dermcidin, compared with normal patients
Psychological stress correlated with onset/exacerbation of
disease; can be partially restored with topical
glucocorticoid receptor antagonists; glucocorticoids
suggested to modulate nAChR activation
High variability of nAChR subtype expression throughout
the stratum corneum, suggestive of erroneous cholinergic
signaling
Ellison et al., 2000; Ong et al., 2002; Raap et al., 2003;
Kurzen and Schallreuter, 2004; Rieg et al., 2005; Choi et al.,
2006; Howell et al., 2006b
Psoriasis High expression of AMPs (LL-37, hbD2, psoriasin, and
elafin/SKALP) in skin lesions; greater resistance to infection
Elevated SLURP-2, an a3nAChR signaling cofactor
Stress triggers disease onset/exacerbation; patients who
believe their psoriasis can be induced by stress exhibit an
altered HPA response, resulting in decreased cortisol levels
Autoimmune feedback loop via LL-37 binding to self DNA;
enhanced T-cell response
Smoking is the most prominent environmental risk factor
thus far described
Arnetz et al., 1985; Madsen et al., 1992; Nonomura et al.,
1994; Harder et al., 1997; Tsuji et al., 2003; O’Leary et al.,
2004; Fortune et al., 2005; Naldi et al., 2005; Richards
et al., 2005; Arredondo et al., 2006; Lande et al., 2007;
Evers et al., 2010
Mal de Meleda Genetic mutation in SLURP-1, an a7nAChR cofactor;
a7nAChR signaling indicated in disease pathology
Chimienti et al., 2003, 2007
Rosacea Hyperactive cathelicidin processing; enhanced proteolytic
processing of peptides; increased inflammation; and
ineffective microbe-killing capacity
Clinical onset/exacerbation triggered by stress
Smoking (i.e., nicotine) decreases rosacea severity
Yamasaki et al., 2006, 2007
Pemphigus Autoantibodies against cell–cell junction proteins, leading
to barrier disruption
Autoantibodies against nAChR; m cholinergic signaling
disrupts normal barrier integrity
Psychological stress correlated with disease onset/
exacerbation
Nguyen et al., 2000a,b, 2001
Palmoplantar pustulosis Irregular distribution/expression patterns of a3nAChR and
a7nAChR throughout the stratum corneum
Strongly correlated with smoking status (i.e., nicotine
exposure)
Hagforsen et al., 2002
Abbreviations: AMP, antimicrobial peptide; hbD, human beta-defensin; HPA, hypothalamic–pituitary–adrenal axis; nAChR, nicotinic acetylcholine receptor;
SLURP-1, secreted mammalian Ly-6/uPAR-related protein-1; SLURP-2, secreted mammalian Ly-6/uPAR-related protein-2.
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the epidermis (Kurzen et al., 2004; Figure 2). Keratinocyte
transition from the granular cell to the flattened corneocyte is
facilitated by ACh to induce apoptotic secretion, which refers
to the sporadic extrusion of cytoplasmic components and the
release of humectants to prevent epidermal water loss (Nguyen
et al., 2001). Knockdown of a7nAChR in cultured keratino-
cytes blocked terminal differentiation, which was coupled to
the increased expression of proapoptotic signaling factors.
Furthermore, the inhibition of a7nAChR signaling using the
pharmacological antagonist a-bungarotoxin promoted cell
cycle progression (Arredondo et al., 2003). This suggests that
a7nAChR signaling facilitates normal apoptotic signals to
generate the stratum corneum. Combined pharmacological
nAChR agonist and mAChR antagonist was also found to
increase intracellular Ca2þ and trigger apoptotic secretion
in vitro (Nguyen et al., 2001). Collectively, ACh signaling is
mediated by distinct combinations of nAChRs as keratinocytes
mature, where each subunit regulates a particular cell function
at a specific point in epidermal differentiation. Our recent
observations identifying a novel pathway for keratinocyte AMP
regulation through cholinergic signaling further extends the
functional contribution of ACh to include epidermal barrier
function through elements of the innate immune system.
KERATINOCYTES AS KEY MEDIATORS OF CUTANEOUS
BARRIER FUNCTION
Physical maintenance of skin permeability barrier function by
the stratum corneum
The fundamental purpose of the stratum corneum is to
prevent external water loss and maintain a homeostatic
microenvironment within the epidermis. The stratum cor-
neum defends against pathogen invasion by creating both a
physical and chemical shield mainly comprising lipids and
AMPs, respectively. Corneocytes are terminally differentiated
keratinocyte cells located in the stratum corneum, which
comprise both the physical and chemical barrier to protect
the skin against physical insult, ultraviolet light, chemical
exposure, and microbial invasion, as well as prevent water
and electrolyte loss into the external environment (Feingold,
2009). The physical permeability barrier is created by the
presence of a hydrophobic extracellular matrix composed of
free fatty acids (FFAs), cholesterol, and ceramides secreted
from lamellar bodies, which are secretory organelles unique
to keratinocytes (Rassner et al., 1999).
An effective permeability barrier depends on tight regula-
tion and organization of cholesterols, ceramides, and FFAs
within the stratum corneum interstices (reviewed in Elias,
2007; Cork et al., 2009; Ahrens et al., 2011; Borkowski and
Gallo, 2011). Strong cell–cell physical associations are created
by cellular desmosomal junctions and secretion of lipid
species from lamellar bodies, which covalently bind cell
membranes and form the corneocyte lipid envelope (Behne
et al., 2000). Experimentally, transepidermal water loss
measurements are a useful biomarker for determining the
integrity and health of the stratum corneum (Kalia et al., 2000).
Barrier recovery can be determined by measuring changes in
transepidermal water loss values following barrier disruption
via tape stripping or acetone treatment. Tape stripping is a type
of superficial wounding that physically removes the corneo-
cyte layer (Pinkus, 1951). Contradictory to earlier reports
suggesting that acetone treatment extracted epidermal lipids
while leaving the corneocyte layer mostly intact, it was
recently demonstrated that acetone treatment also removes the
corneocyte layer, but only mildly extracts lipids (Rissmann
et al., 2009). Elevated transepidermal water loss values can be
observed following chemical exposure, physical disruption, or
several disease states, including but not limited to AD (Gupta
et al., 2008), perioral dermatitis (Dirschka et al., 2004), and
psoriasis (Motta et al., 1994).
Initial studies aimed at determining factors that negatively
regulate epidermal lipid synthesis began by investigating the
influence of psychological stress created by either immobi-
lization or crowding of mice (Denda et al., 1998). Stressed
animals exhibited delayed barrier recovery following barrier
disruption via tape stripping indicated by higher transepider-
mal water loss measurements. Conversely, pretreatment with
a sedative or GC receptor antagonist prevented the altered
barrier recovery observed (Denda et al., 1998, 2000).
Psychological stress in mice was also shown to decrease
epidermal cell proliferation and differentiation while simul-
taneously reducing the production and secretion of lamellar
bodies (Choi et al., 2005). This effect was reversed by topical
lipid application, or systemic GC receptor antagonist admin-
istration (Choi et al., 2006), establishing a direct effect of
neuroendocrine mediators on biochemical pathways re-
quired for normal skin barrier homeostasis. Preliminary
studies in healthy humans using two validated measures,
mood states and the perceived stress scale, demonstrated the
nAChR expression
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Figure 2. Expression of nicotinic acetylcholine receptor (nAChR) subtypes is
dependent upon differentiation, free ACh concentration, and free Ca2þ
concentration gradients. The nAChR superfamily of ligand-gated ionotropic
receptors are differentially expressed during the course of keratinocyte
differentiation. Corneocyte cells comprising the top layer of the epidermis
(stratum corneum) express primarily a7nAChR. Transitional (prickle)
keratinocytes located in the middle layer of the epidermis express primarily
a3(b2/b4)a5nAChR. Immature (basal) keratinocytes located within the base
layer of the epidermis express primarily a3b2 or nAChRa3b4nAChR. All
keratinocyte cells appear to express a9nAChR. Activation of each nAChR
subtype is associated with a different cellular response, including apoptosis,
cornification, proliferation, migration, and differentiation. Atypical expression
of specific nAChR subtypes throughout the epidermis has been correlated
with disease. The gradients on the right represent the state of differentiation
and the concentrations of ACh and free calcium, with the greatest degree of
differentiation and highest ACh and free calcium concentrations occurring at
the interface with the external environment (e.g., stratum corneum).
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first correlation between perceived psychological stress and
deteriorated cutaneous barriers, providing the first evidence
that stress-induced alterations in the epithelial barrier may
trigger the onset of clinical manifestations of skin disease
pathogenesis (Garg et al., 2001).
AMPs are multifunctional peptides that not only protect
against microbial invasion and insult through direct pathogen
killing, but also signal to the innate immune system and
contribute to the generation and maintenance of the
permeability barrier. In addition to its antimicrobial function,
one AMP in particular, murine cathelicidin (CAMP), was
found to have a crucial role in upholding epidermal barrier
homeostasis. Mice deficient in cathelicidin (Camp/) have a
diminished capacity to restrict barrier permeability, as they
exhibit delayed barrier recovery following tape stripping
(Aberg et al., 2008). Camp/ mice also display decreased
lamellar body formation and secretion, and profound lipid
composition defects compared with wild-type mice (Aberg
et al., 2008). The role of AMPs in protection against
cutaneous infection is discussed below.
Chemical maintenance of the skin barrier by lipids and AMPs
Apart from the physical barrier comprising keratinocytes and
lipids, the skin contains a chemical barrier partially consisting
of lipids, but largely consisting of AMPs to restrict microbial
growth on the surface of the skin and help maintain barrier
integrity (reviewed in Braff et al., 2005). Long-chain bases,
such as sphingosines, and FFAs, such as lauric acid and
sapienic acid, are derived from the partial hydrolysis of
ceramide by ceramidases (Houben et al., 2006), and are the
most potent antimicrobial lipid species in the stratum
corneum (Miller et al., 1988; Bibel et al., 1992). Sphingoid
bases have broad antifungal and antimicrobial properties
against a wide range of skin pathogens, including Gram-
positive bacteria (e.g., Staphylococcus aureus, S. epidermidis,
and S.s pyogenes), Gram-negative bacteria (e.g., Escherichia
coli), and yeast (e.g., Candida albicans; Drake et al., 2008).
FFAs are selective against Gram-positive bacteria (e.g.,
S. aureus), but not Gram-negative bacteria and yeast (e.g.,
C. albicans; Bibel et al., 1989, 1992, 1995; Aly et al., 1994).
The importance of understanding the contribution of FFAs to
host defense is highlighted by the fact that different combina-
tions of FFAs may exert different antimicrobial potencies
against microbial species. For example, sapienic acid is more
effective for the treatment of methicillin-resistant S. aureus
infection than mupirocin, the current ‘‘gold standard’’ of
treatment of methicillin-resistant S. aureus infections (Drake
et al., 2008). Overall, the lipid component of the skin
permeability barrier contributes to antimicrobial defense in
parallel with AMPs.
AMPs are an evolutionarily conserved component of the
innate immune system that function at the external periphery
as the initial line of defense against invasion by pathogens
(Gallo and Nizet, 2003; Ganz, 2003; Nizet and Gallo, 2003).
Several families of AMPs, including cathelicidins (LL-37),
defensins, and chromogranins, are expressed in immune cells
(e.g., neutrophils, natural killer cells, mast cells, and
macrophages), as well as epithelial cells such as sebocytes
and keratinocytes (Agerberth et al., 2000; Di Nardo et al.,
2003; Braff and Gallo, 2006; Lee et al., 2008). To date, there
exist over 20 epidermal AMPs (reviewed in Schauber and
Gallo, 2009). Several key epidermal AMPs, ribonuclease 7,
and lysozyme are constitutively active and expressed at low
basal levels (Harder et al., 2007). Other AMPs, such as
human beta-defensin (hbD)-2 and hbD-3, and the CAMP
cleavage product, LL-37, are only expressed in response to
inflammation (Gudmundsson et al., 1996; Harder et al.,
1997, 2001; Schroder and Harder, 1999; Dorschner et al.,
2001; Nizet et al., 2001; Harder and Schroder, 2002; Glaser
et al., 2005; Pazgier et al., 2006). Other epidermal AMPs,
such as dermcidin, are sweat-gland derived (Schittek et al.,
2001), whereas the S100 protein psoriasin is focally present
at varying levels throughout healthy skin (Glaser et al., 2005)
and induced upon wounding (Lee and Eckert, 2007) or skin
inflammation (Madsen et al., 1991).
Cathelicidin is proteolytically cleaved from the larger
hCAP18 pro-protein into the catalytically active peptide
(human LL-37, murine CAMP) by kallikrein proteases
produced by keratinocytes, or by neutrophil-derived protein-
ase-3 (Hansson et al., 1994; Ekholm et al., 2000). In human
keratinocytes, cathelicidin expression can be augmented in
response to pathogen challenge, vitamin D3 exposure, and
wounding (Dorschner et al., 2001; Butmarc et al., 2004;
Wang et al., 2004; Schauber et al., 2008), where it functions
as natural antibiotics to not only directly eradicate microbial
pathogens, but also coordinate multiple components of the
innate and adaptive immune responses (Brogden et al., 2003;
Kandler et al., 2006). For example, LL-37 can directly
promote the secretion of chemokines from keratinocytes
(Niyonsaba et al., 2007). Furthermore, LL-37 has the capacity
to enhance Toll-like receptor signaling in immune cells and
initiate a cytokine cascade responsible for bacterial recogni-
tion (Niyonsaba et al., 2001), while stimulating the release of
reactive oxygen species from activated neutrophils (Zheng
et al., 2007) to enhance the overall response to infection.
Conflicting reports of LL-37 immunoreactivity throughout the
epidermis have been described, with some demonstrating
localization in the extracellular space between the stratum
granulosum and stratum corneum (Goo et al., 2010) and
others to the stratum basale ((Heilborn et al., 2003; Mallbris
et al., 2010). As the expression of specific nAChR and
mAChR subtypes varies throughout the epidermis, under-
standing how ACh contributes to LL-37 expression/activity
will require further investigation into its localization.
The role of AMPs in keratinocyte innate defense has been
primarily described using murine model systems. However, it
should be noted that although most AMPs appear to be
conserved between mice and humans, several important
differences between expression patterns and regulatory
mechanisms have been described. For example, humans
have both epidermal and neutrophil-derived defensins,
whereas mice only express defensins in epithelial cells,
suggesting that murine and human innate immune responses
may be significantly different (Eisenhauer and Lehrer, 1992;
Harder et al., 1997). The mechanisms regulating human
CAMP and murine Camp also vary considerable with respect
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to the cathelicidin promoter. In humans, CAMP transcription
requires binding of the vitamin D receptor to the vitamin D
response element consensus sequence in the cathelicidin
promoter (Gombart et al., 2005). However, the nocturnal
nature of mice likely explains the absence of the vitamin D
response element consensus sequence in the murine Camp
promoter (Gombart et al., 2005). Recent studies in mice with
a keratinocyte-specific deletion of hypoxia-inducible factor-
1a indicates that Camp expression in mice is partially
regulated by hypoxia-inducible factor-1a. Hypoxia-inducible
factor-1a-null neutrophils from these mice presented with
reduced levels of cathelicidin and exhibited a decreased
phagocytic capacity of skin pathogens (Peyssonnaux et al.,
2005). Together, the variability in AMP regulation between
species is of critical importance and should be taken into
consideration when interpreting data acquired from human
and mouse experiments. A more relevant model system
would be the rhesus monkey, as defensin and cathelicidin
AMPs are expressed in the same cell types and tissues as in
humans (Bals et al., 2001), and the cathelicidin promoter
contains vitamin D response elements (Gombart et al., 2005),
suggesting that similar mechanisms of AMP transcriptional
regulation occur between humans and nonhuman primates.
THE ROLE OF a7nAChR IN KERATINOCYE BARRIER
FUNCTION: LESSONS FROM MURINE KNOCKOUTS
Although numerous nAChR subtypes exist in the epidermis,
there is evidence to suggest that similar to the systemic,
neuronal cholinergic anti-inflammatory pathway, the
a7nAChR subtype is likely to have a significant role in the
regulation of the local cutaneous innate immune and barrier
function. Loss of a7nAChR expression in Chrna7/ mice
resulted in profound decreases (34–56%) in genes related to
terminal differentiation, including murine filaggrin, cytoker-
atin-1, and cytokeratin-10. Furthermore, these mice also
displayed a reduction in the production of extracellular
matrix proteins collagen-1a1 and elastin, and metallopro-
teinase-1 (Arredondo et al., 2002). Significant differences
between the histology of Chrna7/ and Chrna7þ /þ were
observed in 1- to 3-week-old mice, where Chrna7þ /þ skin
exhibited the normal, upper compact horny layer derived
from dead corneocytes, 1–2 layers of live, nucleated
keratinocytes, and a single row of suprabasal keratinocytes.
In contrast, Chrna7/ skin had a loose, widened corneocyte
layer, 1–3 layers of granulated keratinocytes, and 1–3 extra
rows of suprabasilar enlarged keratinocytes, a phenotype
consistent with retention hyperkeratosis (Arredondo et al.,
2002). Interestingly, Chrna7/ mice also show a differential
gene expression of the other nAChR subunits, suggesting that
a compensatory mechanism may have developed to regulate
keratinocyte cell cycle progression, apoptosis, and terminal
differentiation genes in the absence of a7nAChR signaling
(Arredondo et al., 2002).
LINKING CHOLINERGIC SIGNALING WITH EPIDERMAL
AMP ACTIVITY AND SUSCEPTIBILITY TO INFECTION
For decades, it has been well documented that stress
strongly correlates with an increased incidence of infection
(Locke, 1982). Only recently have we begun to elucidate
the neuroendrocrine contribution of epithelial immunity.
Stressed individuals have increased epithelial ACh levels
(Schlereth et al., 2007) and are more susceptible to
opportunistic infections (Wu et al., 2005; Ashcraft et al.,
2008). Overactivation of the stress-response pathways, as
observed during chronic stress, results in a relative state of
immunosuppression that can be partly attributed to activation
of the cholinergic anti-inflammatory pathway described
earlier.
As the cholinergic system is directly involved in systemic
immunosuppression, it was likely that non-neuronal choli-
nergic activation could suppress the local cutaneous AMP
response in keratinocytes. Normal human epidermal kerati-
nocytes (NHEKs) stimulated with the bioactive form of
vitamin D, 1,25-dihydroxy vitamin D3 (VD3), and the Toll-
like receptor 2/6 agonist, macrophage-activating lipoprotein-
2 (MALP-2), allows for maximal gene and protein expression
of both cathelicidin and b-defensin-2 through differentiation
and bacterial stimuli, respectively (Weber et al., 2005;
Schauber et al., 2006). Our initial results identified that the
in vitro expression of CAMP in NHEKs was induced B100-
fold over baseline levels by VD3þMALP-2, whereas the
presence of 0.01 nM ACh resulted in an B50% reduction in
CAMP (Radek et al., 2010). We observed a similar suppres-
sion of hbD-2 gene and protein expression by ACh compared
with the MALP-2 alone. To further elucidate the specific
receptor subtype mediating the dampening response by ACh,
additional experiments were conducted using two pharma-
cological antagonists, a-bungarotoxin, which is selective for
the a7nAChR subunit, and mecamylamine, with known
selectivity for a3b4nAChR subtypes (Grando et al., 2006), or
an endogenous epidermal nAChR antagonist, catestatin (Cst;
Radek et al., 2008). CAMP suppression by ACh was restored
by the presence of Cst and mecamylamine, with maximal
restoration observed with a-bungarotoxin. The induction of
CAMP and b-defensin expression paralleled the capacity of
NHEKs to restrict the growth of the major skin pathogen
S. aureus. Lysates of NHEKs treated with VD3þMALP-2
restricted staphylococcal growth by 90% as compared with
lysates from untreated cells. Treatment with 0.01 nM ACh
suppressed the antimicrobial activity of VD3þMALP-2
lysates to that of untreated cell lysates. This effect was again
restored by the presence of Cst or a-bungarotoxin. This
strongly indicates that nAChR signaling dampens the direct
extractable antibacterial activity in NHEKs consistent with the
critical role of AMPs in this response (Radek et al., 2010).
Treatment of NHEKs with muscarine, a mAChR-specific
agonist, or propranolol, a b-adrenergic pathway agonist, was
unable to suppress the induced AMP expression observed
with VD3/MALP-2 treatment, suggesting that ACh regulation
of AMP expression in keratinocytes is through direct
activation of nAChRs (Radek et al., 2010). The observation
that AMP suppression by ACh could be fully restored by the
presence of a-bungarotoxin, and mostly restored by the
addition of mecamylamine or Cst, suggests that ACh likely
facilitates AMP suppression via a7nAChR, similar to the
neuronal cholinergic response to infection (Tracey, 2007).
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Our results indicate that the changes in direct extractable
antibacterial activity in these NHEKs lysates was likely due
to, in part, decreased cathelicidin and hbD-2 expression.
However, it is possible that the levels of other inducible
AMPs (e.g., ribonuclease 7 and hbD-3) or constitutive AMPs
(e.g., psoriasin), normally increased by the presence of
bacterial membrane components, were also suppressed by
the presence of ACh (Harder et al., 2001; Harder and
Schroder, 2002). Similar studies designed to identify changes
in specific AMPs are currently in progress.
Cst was initially identified as an AMP, as it exhibited a
broad-spectrum killing against several pathogens including
S. aureus, group A Streptococcus, E. coli, Pseudomonas
aeruginosa, and C. albicans, as well as several varieties of
filamentous fungi in vitro (Briolat et al., 2005; Radek et al.,
2008). As the concentration of Cst required for microbicidal
killing was much higher than levels observed in normal skin
(Radek et al., 2008), we proposed that the antimicrobial
properties may be secondary to its primary role as a natural,
endogenous nAChR antagonist. Similar to several neuroen-
docrine-derived molecules, such as a-melanocyte-stimulat-
ing hormone, neurokinin-1, and adrenomedullin, Cst may
exhibit microbicidal activity due to their inherently small,
cationic, amphipathic structure (reviewed in Radek and
Gallo, 2007). In our studies, we found that AMP suppression
by ACh was mostly restored by the presence of Cst, indicating
that Cst can block the effects of ACh by functioning primarily
as an endogenous nAChR antagonist (Radek et al., 2010).
To verify the functional relevance of cholinergic activation
and keratinocyte AMP regulation in vivo, we used a
pharmacological and genetic approach using two murine
models of cholinergic activation (Radek et al., 2010). For the
pharmacological approach, we applied a-bungarotoxin or
vehicle topically to psychologically stressed mice (e.g.,
insomnia stress) and assessed their susceptibility to infection.
We found that stressed mice treated with a-bungarotoxin
were less susceptible to group A Streptococcus infection
compared with vehicle-treated mice, as indicated by smaller
lesion size, less surviving bacteria in lesions, and lower
dissemination into distal organs (Radek et al., 2010). Mice
treated topically with nicotine (in the absence of stress)
demonstrated a significant reduction in extractable AMP
activity, indicating that direct activation of nAChRs nega-
tively regulates AMP expression (Radek et al., 2010). We later
defined the role of nAChR activation in regulating AMP
activity in the skin by employing a genetic approach by using
CHGA/ mice, which lack the endogenous nAChR antago-
nist Cst and hence exhibit unopposed nAChR activation.
CHGA/ mice were significantly more susceptible to both
S. aureus and group A Streptococcus skin infection. These
mice also exhibited a significant reduction in extractable
AMP activity, which was restored by the presence of topical
a-bungarotoxin. Together, these data suggested that the
regulation of epidermal AMP expression and activity by
ACh is highly dependent on the a7nAChR subtype, but may
also involve other subtypes to a lesser degree (Radek et al.,
2010). In addition, the increase in bacterial survival following
prolonged nAChR activation was likely the result of several
immunosuppressive responses, including AMP-dependent
production of proinflammatory cytokines and enhancement
of bacterial survival and proliferation through changes in the
epidermal microenvironment (Freestone and Lyte, 2008). In
humans, a likely detrimental consequence of a diminished
epidermal immune response following nAChR activation
would lead to bacterial dissemination from initial sites of
infection and colonization in distal tissues and organs.
Our previous investigations also provided a critical piece
of data that nAChR-mediated cathelicidin dysregulation is a
potential mechanism for increased susceptibility to infection.
We found that stress did not augment the susceptibility to
infection in cathelicidin-deficient (Camp/) or CHGA/
mice. This indicates that nAChR activation is a major
contributing factor to the suppression of the AMP response
to infection during prolonged nAChR activation by stress, and
that cathelicidin is a key AMP influenced by cholinergic
activation of nAChRs (Radek et al., 2010). If other AMPs or
neuroendocrine mediators were more involved in AMP
suppression, we would expect larger lesions and greater
bacterial burden in both Camp/ and CHGA/ mice
following stress. In addition, cathelicidin is an autocrine
regulator of the response to purinergic agonists through
modification of receptors involved in the tissue response to
inflammation or injury, indicating a direct role for cathe-
licidin in cholinergic-mediated immunosuppression (Pochet
et al., 2006). Thus, the global suppression of AMP activity
and cathelicidin seen with nAChR activation may exacerbate
immunosuppression by blocking necessary stimulation of
downstream immune responses that are AMP dependent.
IMPLICATIONS FOR THE ROLE OF CHOLINERGIC
ACTIVATION IN THE DEVELOPMENT OF SKIN
PATHOLOGIES
Delayed wound healing
AMPs have an important role in modulating wound healing
responses by increasing the expression of chemokines and
chemokine receptors, stimulating epithelial proliferation, and
promoting adaptive immune responses and angiogenesis
(Scott et al., 2002; Mookherjee and Hancock, 2007; Lai
and Gallo, 2009). Therefore, a defective permeability barrier,
arising from altered skin pH, lipid composition, or flawed
cell–cell junctions, in addition to an insufficient AMP
repertoire, can result in overactive cytokine/chemokine
cascades and can foster a destructive inflammatory milieu.
As AMPs have a multifunctional role in regulating innate
immune responses, inflammation, and barrier function, it is
critical to maintain their homeostatic balance to allow for
maximal wound repair processes.
Cholinergic signaling has been implicated in the regula-
tion of re-epithelialization during tissue repair. Immediately
following barrier disruption and wounding, proinflammatory
cytokines, such as TNF-a, IL-1-a, and IL-1b, are released by
immune and keratinocytic cells to stimulate cellular prolif-
eration required for epidermal regeneration (e.g., re-epithe-
lialization; Wood et al., 1992; Nickoloff and Naidu, 1994). At
the onset of re-epithelialization, keratinocyte cell–cell des-
mosomal and hemidesmosomal connections are dissolved,
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followed by the development of peripheral cytoplasmic actin
filaments (Gabbiani et al., 1978; Goliger and Paul, 1995).
Concurrently, keratinocyte integrin expression increases to
allow for lateral migration across the wound bed (Clark,
1990; Clark et al., 1996), which ceases when keratinocytes
collide to form new cell–cell junctions and ensue with
terminal differentiation (Adams and Watt, 1990; Martin,
1997; Singer and Clark, 1999). Cholinergic signaling by
several nAChRs was found to be directly involved in
keratinocyte chemotaxis and chemokinesis, respectively. In
in vitro migration assays, reorganization of a7nAChRs along
the leading edge of keratinocytes occurred before the
conventional crescent-shaped formation and directional
migration of human keratinocytes in the presence of a
chemoattractant, whereas several nAChRs were found to
localize with integrin-b1 expressed on the keratinocyte cell
membrane (Chernyavsky et al., 2004). Experimental evidence
also suggests that a9nAChR activation leads to downstream
phosphorylation of cytoskelatal proteins required for cell
motility (Szonyi et al., 1999) and keratinocyte cell–cell
adhesion (Nguyen et al., 2000a). Collectively, this suggests
that ACh likely contributes to both the initiation and
termination of re-epithelialization during wound repair to
re-establish the epidermal permeability barrier. (Grando
et al., 2006).
AD and psoriasis
A key factor in a myriad of cutaneous inflammatory diseases
includes AMPs. Up to 90% of AD skin lesions are typically
colonized by S. aureus (Leung, 2003). In the past, greater
susceptibility was attributed to an overall decrease in AMP
expression, as it was demonstrated that cathelicidin (LL-37),
hbD-2, and hbD-3 levels were all decreased in AD skin when
compared with psoriatic skin (Ong et al., 2002). Therefore, it
was presumed that the overall decrease in AMP expression
directly resulted in suppressed antimicrobial potential and a
compromised barrier. More recently, a study with a large
patient cohort of atopic excema, psoriatic, and normal
controls demonstrated that atopic excema lesions have LL-
37 levels similar to that of normal, non-lesional skin, and
healthy skin from normal donors (Gambichler et al., 2008).
Psoriasin secretion was also profoundly increased (up to
1,500-fold) when comparing AD skin with healthy skin from
the same individual (Glaser et al., 2009). These conflicting
reports highlight the importance of understanding the factors
that contribute to AMP regulation. Although the baseline
levels of AMP expression in AD patients may be equal to or
higher than normal, uninjured skin, the antimicrobial
potential of these AMPs remains to be determined. It has
been demonstrated that the increased LL-37 expression
following injury observed in healthy volunteers was not
observed in AD lesions (Mallbris et al., 2010), suggesting that
although the baseline level of LL-37 among normal, atopic,
and psoriatic skin appears about the same, increased
microbial colonization likely arises from the inability to
induce LL-37 following wounding or in the presence of active
infection. Furthermore, it has been shown that Th2 cytokines,
IL-4 and IL-13, directly downregulate AMP expression in
cultured human keratinocytes (Ong et al., 2002; Nomura
et al., 2003). In parallel, AD patients have an elevated Th2
cytokine milieu, at least in comparison with psoriatic skin
(Nomura et al., 2003). This altered cytokine milieu is
believed to directly suppress the AMP response to injury
and infection in the skin, providing further evidence that the
increased susceptibility to infection observed in AD patients
is multifaceted, arising from defects in innate antimicrobial
responses, as well as adaptive immunity and cytokine
responses. These observations emphasize the importance of
identifying common mechanisms behind AMP induction and
suppression that may yield unconventional therapeutic
interventions that can be customized to treat cutaneous
disorders with AMP dysregulation as a major contributing
factor.
AD is a common skin disease in which clinical onset is
usually triggered by environmental or psychological stress
(Raap et al., 2003). Variable differences in expression of ACh
receptor subunits have been observed in patients with AD, as
well as in response to minimal trauma (Kurzen and
Schallreuter, 2004). Patients with AD have a significant
increase (14-fold) in ACh expression in the skin, as compared
with normal individuals (Wessler et al., 2003). Moreover,
ACh contributes to the pathophysiological characteristics of
AD, such as increased pruritis, or itch, due to its ability to
cause vasodilatation and the wheal and flare reaction (Heyer
et al., 1997; Rukwied and Heyer, 1999; Wessler et al., 2003).
NC/Nga mice exhibit increased serum IgE, scaly AD-like
lesions, and mast cell accumulation similar to serum and skin
lesions of AD patients (Suto et al., 1999), and these mice are
frequently used as a murine model of AD. Psychological
stress was shown to trigger the development of these
histopathologies in NC/Nga mice, where pretreatment with
corticotropin-releasing hormone (CRH), a neurogenic peptide
released in response to cholinergic stimulation, completely
prevented the onset of AD lesions in these animals (Amano
et al., 2008). Epidermal cells expressing CRH receptors may
have a role in the mechanism by which stress-induced
cholinergic activation triggers the onset and exacerbation of
AD (Amano et al., 2008). These data strongly suggest a direct
role for ACh and cholinergic signaling in the development of
AD pathophysiology.
Lesions from patients with psoriasis show epidermal
hyperplasia and increased AMP expression, excess inflam-
mation, and a diminished susceptibility to infection (Madsen
et al., 1991; Ong et al., 2002; Rieg et al., 2005; Howell et al.,
2006a). Extensive studies in humans indicate a direct
interaction between smoking (e.g., exposure to nicotine)
and the development of psoriatic arthritis through genetic
polymorphisms in the gene encoding for the Th2 cytokine, IL-
13 (Duffin et al., 2009). The clinical onset and exacerbation
of psoriasis is associated with environmental and psycholo-
gical stress, as well as increased CRH levels (Kim et al.,
2007). As CRH release is dependent upon cholinergic
activation in the hypothalamus (Karanth et al., 1999), it is
possible that the increased CRH levels are a result of
enhanced cholinergic regulation in the skin. Furthermore,
it was recently demonstrated that secreted mammalian
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Ly-6/uPAR-related protein-1 is upregulated 3-fold in hyper-
proliferative skin from patients with psoriasis (Tsuji et al.,
2003; Arredondo et al., 2006). Secreted mammalian Ly-6/
uPAR-related protein-2 appears to preferentially bind the
a3nAChR subtype, which indicates a potential role for this
nAChR subtype in the progression of psoriasis (Arredondo
et al., 2006).
Pemphigus
Pemphigus is a rare, blistering autoimmune skin disorder that
targets the skin and mucous membranes, and is mediated by
the production of autoantibodies against keratinocyte anti-
gens, including desmogleins, proteins important for cell–cell
junctions, and also several nAChRs (reviewed in Grando,
2000). Pemphigus patients have reported that an emotional,
stressful event is typically a worsening or precipitating factor
of pemphigus (Morell-Dubois et al., 2008). In neonatal mice,
nAChR antibodies can induce pemphigus-like lesions,
suggesting that these receptors may contribute to the
pathogenesis of Pemphigus vulgaris (Nguyen et al., 2000b).
The role of AMPs in this disease has yet to be elucidated.
However, the experimental evidence described here suggests
that it is highly likely that the result of desensitized nAChR
signaling in keratinocytes could potentially augment cuta-
neous inflammation and/or AMP expression to further
aggravate this disease.
Mal de Meleda
Mal de Meleda is an autosomal recessive inflammatory and
keratosis palmoplantar disorder, resulting from mutation of
secreted mammalian Ly-6/uPAR-related protein-1 (Arredondo
et al., 2005), which functions as a cofactor to fine-tune
cholinergic signaling in keratinocytes. Secreted mammalian
Ly-6/uPAR-related protein-1 facilitates keratinization and
apoptosis (Mastrangeli et al., 2003) and shows high amino-
acid composition homology with a-bungarotoxin to function
as an allosteric agonist to potentiate acetlycholine-mediated
signaling via the a7nAChR subtype (Arredondo et al., 2005;
Grando, 2008).
Rosacea
Patients with rosacea present with excessive facial skin
inflammation determined to be triggered, in part, by
increased expression of cutaneous serine proteases, kallikrein
5 and 7. Overactive serine protease activity in the stratum
corneum results in shorter LL-37 peptides possessing im-
munostimulatory activity due to additional posttranslational
cleavage (Yamasaki et al., 2007). Clinical observation has
indicated that rosacea symptoms improve when patients are
actively smoking (Mills, 1998), whereas symptoms appear to
worsen upon cessation of nicotine exposure. This insinuates
that nAChR activation, at least in some cases, may serve a
protective role to prevent inflammation.
Netherton’s syndrome
Patients with Netherton’s syndrome, a genetically conferred
disease, are predisposed to AD and demonstrate a higher risk
for cutaneous infection (Stryk et al., 1999; Chao et al., 2005).
Patients with Netherton’s syndrome carry a mutation in the
serine protease inhibitor Kazal-type 5 gene, which codes for
lymphoepithelial Kazal-type-related inhibitor (Magert et al.,
1999), a serine proteinase required for the processing of
kallikrein proteases into active form (Schechter et al., 2005).
Loss of lymphoepithelial Kazal-type-related inhibitor may
contribute to AD predisposition by altering expression of both
structural/cell–cell junction proteins, therefore destabilizing
the epidermal barrier. In parallel, the observed increase in the
expression of kallikrein proteases in this disease likely
augments the proteolytic processing of AMPs and, conse-
quently, inflammation (as indicated for rosacea above).
Vitiligo
Vitiligo is a chronic skin disorder in which loss of pigment
results in irregular white patches. The abundance of
acetylcholinesterase, the enzyme responsible for degrading
ACh, is considerably reduced in vitiliginous skin during
depigmentation, resulting in elevated ACh levels and con-
comitant pruritis (Iyengar, 1989). Although cholinergic
signaling has not been directly correlated with this disease,
high ACh levels make it likely that excessive nAChR signaling
contributes to disease pathology.
BOTULINUM TOXIN-A AS A POTENTIAL
ANTI-CHOLINERGIC THERAPEUTIC FOR TREATING
SKIN DERMATOSES
Botulinum toxin-A inhibits the release of ACh from pre-
synaptic vesicles (Hallett, 2000; Huang et al., 2000), making
it a potential therapy for inflammatory diseases correlated
with hyperactive nAChR signaling. Several clinical trials have
already reported positive outcomes. Subcutaneous injection
of botulinum toxin-A in numerous AD clinical trials improved
pruritis symptoms (Swartling et al., 2002; Wollina and
Karamfilov, 2002). Successful treatments of acne, notalgia
paresthetica, and inverse psoriasis have also been described
(Diamond and Jankovic, 2006). In a double-blind, placebo-
controlled study of human patients with normal skin,
subcutaneous injection of botulinum toxin-A decreased the
itch intensity, blood flow, and neurogenic inflammation in
response to the histamine prick test (Gazerani et al., 2009).
Thus, blockade of cholinergic signaling in targeted regions of
the skin may help alleviate clinical manifestations of
cutaneous diseases associated with ACh-mediated symptoms.
FUTURE DIRECTIONS
On the basis of the clinical and experimental evidence
presented in this review, it is evident that the cholinergic
anti-inflammatory pathway spans several macro- and micro-
environments to provide a universal network to control
inflammation. In the skin, it remains to be determined
whether neuronal ACh released from neural components in
the skin is functioning in parallel with or independently from
non-neuronal ACh released from keratinocytes to regulate
AMP expression and activity in the epidermis. Our in vitro
results indicate that the epidermis comprises all of the
necessary components to autonomously dampen the epider-
mal AMP response to infection. The local coordination of ACh
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signaling within the epidermis makes topical therapeutics a
promising solution for directly targeting the cells responsible
for ACh-dependent downregulation of AMP expression, and
eliminates the need to systemically target the vagus nerve.
However, it cannot be ruled out that the immunosuppressive
effects of nAChR activation are not multifaceted, where
topical agonists or antagonists may activate other resident skin
cells, including Langerhans and gd-T cells, or sensory nerve
cells to further inhibit inflammatory pathways in the skin.
Elucidating the contribution of each particular nAChR subtype
to keratinocyte AMP production and synthesis of structural
elements necessary for barrier function is critical for devel-
oping unique therapeutic strategies for cutaneous diseases
with AMP function as a central component. Moreover, a high
degree of cross talk likely exists between the three branches of
the stress response. Dissecting the contributions of each
particular stress pathway will be a vital factor in the
development of therapies. A possibility exists that specific
concentrations of ACh must be appropriately maintained
within the stratified epidermis to maintain AMP expression
and activity during periods of acute stress, which is likely
skewed during periods of prolonged stress. This imbalance
will consequently augment nAChR activation, resulting in
immunosuppression and compromised barrier function. Col-
lectively, a complex network of cellular and biochemical
mechanisms facilitate the pathogenesis of skin disease upon
activation of the stress response. Activation of the hypotha-
lamic–pituitary–adrenal axis and the adrenergic system are the
most extensively studied pathways to date, but a greater
emphasis must be made on the role of the cholinergic system
in maintaining the chemical and physical skin barrier.
Ultimately, these investigations will yield new strategies in
the treatment of inflammatory skin disorders.
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